Clinically used antirheumatic agent auranofin is a proteasomal deubiquitinase inhibitor and inhibits tumor growth

@inproceedings{Liu2014ClinicallyUA,
  title={Clinically used antirheumatic agent auranofin is a proteasomal
deubiquitinase inhibitor and inhibits tumor growth},
  author={Ningning Liu and Xiaofen Li and Hongbiao Huang and Chong Zhao and Siyan Liao and Changshan Yang and Shouting Liu and Wenbin Song and Xiaoyu Lu and Xiaoying Lan and Xin Mao Chen and Songgang Yi and Li Xu and Lili Jiang and Canguo Zhao and Xiaoxian Dong and Ping Zhou and Shujue Li and Shunqing Wang and Xianping Shi and Ping Q. Dou and Xuejun Wang and Jinbao Liu},
  booktitle={Oncotarget},
  year={2014}
}
Proteasomes are attractive emerging targets for anti-cancer therapies. Auranofin (Aur), a gold-containing compound clinically used to treat rheumatic arthritis, was recently approved by US Food and Drug Administration for Phase II clinical trial to treat cancer but its anti-cancer mechanism is poorly understood. Here we report that (i) Aur shows proteasome… CONTINUE READING